Palisade Bio, Inc. PALI
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -50.64%
- 1 year
- -40.21%
- Open
- 1.18
- Prev close
- 1.19
- Mkt cap
- 202.15M
- Vol
- 3.09M
- Avg vol
- 2.75M
- EPS
- 0.60
- P/E
- 1.93
- Div yield
- 0.00%
More statistics
- Low
- 1.12
- High
- 1.20
- Forward P/E
- -0.19
- Beta
- 1.33
- Short ratio
- 0.29
- Inst. own
- 3.58%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.61
- 200-d avg
- 4.17
- 1y target
- 30.33
News
-
4 days ago benzinga.com
Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
4 days ago globenewswire.com
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability
-
1 week ago benzinga.com
Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated
linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
-
2 weeks ago benzinga.com
Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo…
-
3 weeks ago benzinga.com
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.